Jefferies & Co. is out with a research report on Optimer Pharm. OPTR and it has a Buy rating and a $17 price target on shares.
In a note to clients, Jefferies & Co. writes, "Given much better-than-expected DIFICID sales in its early launch cycle (U.S. launch on 7/18/11), upcoming EU approval and launch by partner Astellas could also provide apotential upside surprise. While EU approval is widely expected (so was FDA approval), potential milestones of ~$68M from Astellas
upon approval and first launch in Europe would strengthen its cash position (sufficient until our projected profitability in 2014)."
Shares of OPTR are up 93 cents to $14.97 today.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in